Zydus Lifesciences Pioneers Dual Vaccine for Global Child Health

Zydus Lifesciences is developing a combination vaccine targeting shigellosis and typhoid, with support from the Gates Foundation. The effort focuses on early-stage development and animal studies. Aimed at children under five, this initiative leverages Zydus' WHO prequalified Typhoid vaccine to tackle enteric diseases in endemic areas.

Zydus Lifesciences announced on Tuesday plans to develop a combination vaccine against shigellosis and typhoid. Supported by the Gates Foundation, the initiative will involve early-stage development and significant preclinical studies.

The project, scheduled to begin in March 2025, aims to protect children under five in areas where these diseases are prevalent. A collaboration will leverage the company's existing WHO prequalified Typhoid vaccine alongside a Shigella vaccine from a partner.

By aligning with key partners, Zydus strives to address global health issues through innovative, affordable vaccine solutions, emphasized by MD Sharvil Patel. This endeavor could have a global impact, notes Gates Foundation Country Director M Hari Menon, highlighting India's role in scientific innovation.

(With inputs from agencies.)